Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated Chinese and Western Medicine for Preclinical Gout (Hyperuricemia)
ChiCTR2300072577Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Hunan University of Chinese Medicine
- Start
- Jun 2023
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of allopurinol and Yunpi Lishi Formula in hyperuricemia and gout (3 arms), sponsored by First Affiliated Hospital of Hunan University of Chinese Medicine. Primary endpoints: blood uric acid and standard-achieving rate of blood uric acid. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
allopurinolYunpi Lishi Formula
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on ChiCTR2300072577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072577.